Long-term results of balloon-occluded retrograde transvenous obliteration for gastric variceal bleeding and risky gastric varices: a 10-year experience

J Gastroenterol Hepatol. 2008 Nov;23(11):1702-9. doi: 10.1111/j.1440-1746.2008.05549.x. Epub 2008 Aug 17.

Abstract

Background and aim: Balloon-occluded retrograde transvenous obliteration (B-RTO) is a new alternative treatment for gastric varices (GVx), but the long-term efficacy is not known. We investigated the long-term effects of B-RTO on rebleeding, prevention of first bleeding, mortality and occurrence of risky esophageal varices (EVx).

Methods: B-RTO was performed in 68 cirrhotic patients with GVx. Twenty patients had recent bleeding, transiently treated by endoscopic Histoacryl injection or balloon tamponade. Forty-eight patients had varices likely to bleed, but no bleeding. After B-RTO, the recurrent bleeding, occurrence of EVx and mortality over the long-term were evaluated.

Results: B-RTO was successfully performed in 63 of 68 patients (92.6%). Varices eradication was confirmed by endoscopy in 61 of 63 patients (96.6%). During follow up, GVx bleeding occurred in two patients (3.2%). The 8-year cumulative rebleeding rates of patients with bleeding and risky GVx were 14% and 0%, respectively. Risky EVx occurred in 10 patients (17%) and the cumulative occurrence rate was 22% in 8 years. The cumulative occurrence rate of risky EVx was higher in GVx with EVx (GOV2-GVx) compared to GVx without EVx (IGV1, P < 0.05). No ectopic variceal bleeding occurred. No patients died from variceal bleeding. Hepatocellular carcinoma was the only significant prognostic factor (P < 0.05).

Conclusion: B-RTO is beneficial over the long-term, despite worsening EVx in some patients, because of excellent treatment efficacy and improved mortality. We believe that B-RTO can become a first-choice radical treatment following hemostasis for gastric variceal bleeding and prophylactic treatment for risky GVx.

MeSH terms

  • Adult
  • Aged
  • Balloon Occlusion* / adverse effects
  • Enbucrilate / therapeutic use
  • Esophageal and Gastric Varices / etiology
  • Esophageal and Gastric Varices / mortality
  • Esophageal and Gastric Varices / pathology
  • Esophageal and Gastric Varices / therapy*
  • Female
  • Gastrointestinal Hemorrhage / etiology
  • Gastrointestinal Hemorrhage / mortality
  • Gastrointestinal Hemorrhage / pathology
  • Gastrointestinal Hemorrhage / therapy*
  • Gastroscopy
  • Hemostatic Techniques* / adverse effects
  • Humans
  • Hypertension, Portal / etiology*
  • Hypertension, Portal / mortality
  • Hypertension, Portal / pathology
  • Hypertension, Portal / therapy
  • Kaplan-Meier Estimate
  • Liver Cirrhosis / complications*
  • Liver Cirrhosis / mortality
  • Liver Cirrhosis / pathology
  • Liver Cirrhosis / therapy
  • Male
  • Middle Aged
  • Oleic Acids / therapeutic use
  • Phlebography
  • Recurrence
  • Risk Assessment
  • Sclerosing Solutions / therapeutic use
  • Sclerotherapy* / adverse effects
  • Time Factors
  • Tissue Adhesives / therapeutic use
  • Treatment Outcome

Substances

  • Oleic Acids
  • Sclerosing Solutions
  • Tissue Adhesives
  • Enbucrilate
  • ethanolamine oleate